DHEAS and cortisol/DHEAS-ratio in recurrent depression: State, or trait predicting 10-year recurrence?

Psychoneuroendocrinology

Volumn 59, Issue , 2015, Pages 91-101

  Mocking, R J T ^a   Pellikaan, C M ^a   Lok, A ^a,b   Assies, J ^a   Ruhe H G ^a,c   Koeter, M W ^a   Visser, I ^a   Bockting, C L ^d,e   Olff, M ^a,b   Schene, A H ^a,f,g  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ARQ PSYCHOTRAUMA EXPERT GROUP   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g RADBOUD UNIVERSITY   (Netherlands)

Author keywords

Cortisol; Dehydroepiandrosterone sulphate (DHEAS); Hypothalamic pituitary adrenal (HPA) axis; Major depressive disorder (MDD); Recurrence; Remission

Indexed keywords

4 AMINOBUTYRIC ACID; HYDROCORTISONE; PRASTERONE SULFATE;

ADULT; AGED; ARTICLE; CIRCADIAN RHYTHM; COGNITIVE THERAPY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; ENDOPHENOTYPE; FEMALE; HIGH RISK PATIENT; HUMAN; HYDROCORTISONE BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DEPRESSION; RECURRENT DISEASE; REMISSION; SYMPTOMATOLOGY; CASE CONTROL STUDY; DEPRESSIVE DISORDER, MAJOR; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; SALIVA; TREATMENT OUTCOME;

ADULT; CASE-CONTROL STUDIES; COGNITIVE THERAPY; CROSS-SECTIONAL STUDIES; DEHYDROEPIANDROSTERONE SULFATE; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PITUITARY-ADRENAL SYSTEM; PREDICTIVE VALUE OF TESTS; RECURRENCE; SALIVA; TREATMENT OUTCOME;

EID: 84937510157     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2015.05.006     Document Type: Article

References (53)

1. Arnold J.T. DHEA metabolism in prostate: for better or worse?. Mol. Cell. Endocrinol. 2009, 301:83-88.
2. Assies J., Visser I., Nicolson N.A., Eggelte T.A., Wekking E.M., Huyser J., Lieverse R., Schene A.H. Elevated salivary dehydroepiandrosterone-sulfate but normal cortisol levels in medicated depressed patients: preliminary findings. Psychiatry Res. 2004, 128:117-122.
3. Assies J., Mocking R.J., Lok A., Ruhé H.G., Pouwer F., Schene A.H. Effects of oxidative stress on fatty acid- and one-carbon-metabolism in psychiatric and cardiovascular disease comorbidity. Acta Psychiatr. Scand. 2014, 130:163-180.
4. Bhagwagar Z., Cowen P.J. 'It's not over when it's over': persistent neurobiological abnormalities in recovered depressed patients. Psychol. Med. 2008, 38:307-313.
5. Bicanic I.A., Postma R.M., Sinnema G., De Roos C., Olff M., Van Wesel F., Van de Putte E.M. Salivary cortisol and dehydroepiandrosterone sulfate in adolescent rape victims with post traumatic stress disorder. Psychoneuroendocrinology 2013, 38:408-415.
6. Bland J.M., Altman D.G. Measurement error proportional to the mean. BMJ 1996, 313:106.
7. Bockting C.L., Schene A.H., Spinhoven P., Koeter M.W., Wouters L.F., Huyser J., Kamphuis J.H. Preventing relapse/recurrence in recurrent depression with cognitive therapy: a randomized controlled trial. J. Consult. Clin. Psychol. 2005, 73:647-657.
8. Bockting C.L., Spinhoven P., Koeter M.W., Wouters L.F., Visser I., Schene A.H., DELTA study group Differential predictors of response to preventive cognitive therapy in recurrent depression: a 2-year prospective study. Psychother. Psychosom. 2006, 75:229-236.
9. Bockting C.L., Lok A., Visser I., Assies J., Koeter M.W., Schene A.H., DELTA study group Lower cortisol levels predict recurrence in remitted patients with recurrent depression: a 5.5 year prospective study. Psychiatry Res. 2012, 200:281-287.
10. Bockting C.L., Mocking R.J., Lok A., Koeter M.W., Schene A.H. Therapygenetics: the 5HTTLPR as a biomarker for response to psychological therapy?. Mol. Psychiatry 2013, 18:744-745.
11. Bortfeld M., Rius M., Konig J., Herold-Mende C., Nies A.T., Keppler D. Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system. Neuroscience 2006, 137:1247-1257.
12. Chen F.R., Raine A., Granger D.A. Tactics for modeling multiple salivary analyte data in relation to behavior problems: additive, ratio, and interaction effects. Psychoneuroendocrinology 2015, 51C:188-200.
13. Clow A., Hucklebridge F., Stalder T., Evans P., Thorn L. The cortisol awakening response: more than a measure of HPA axis function. Neurosci. Biobehav. Rev. 2010, 35:97-103.
14. Davidson M., Marwah A., Sawchuk R.J., Maki K., Marwah P., Weeks C., Lardy H. Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. Clin. Invest. Med. 2000, 23:300-310.
15. Donders A.R., van der Heijden G.J., Stijnen T., Moons K.G. Review: a gentle introduction to imputation of missing values. J. Clin. Epidemiol. 2006, 59:1087-1091.
16. Fabian T.J., Dew M.A., Pollock B.G., Reynolds C.F., Mulsant B.H., Butters M.A., Zmuda M.D., Linares A.M., Trottini M., Kroboth P.D. Endogenous concentrations of DHEA and DHEA-S decrease with remission of depression in older adults. Biol. Psychiatry 2001, 50:767-774.
17. Genud R., Merenlender A., Gispan-Herman I., Maayan R., Weizman A., Yadid G. DHEA lessens depressive-like behavior via GABA-ergic modulation of the mesolimbic system. Neuropsychopharmacology 2009, 34:577-584.
18. Girdler S.S., Lindgren M., Porcu P., Rubinow D.R., Johnson J.L., Morrow A.L. A history of depression in women is associated with an altered GABAergic neuroactive steroid profile. Psychoneuroendocrinology 2012, 37:543-553.
19. Goodyer I.M., Herbert J., Tamplin A., Altham P.M. Recent life events, cortisol, dehydroepiandrosterone and the onset of major depression in high-risk adolescents. Br. J. Psychiatry 2000, 177:499-504.
20. Goodyer I.M., Herbert J., Tamplin A. Psychoendocrine antecedents of persistent first-episode major depression in adolescents: a community-based longitudinal enquiry. Psychol. Med. 2003, 33:601-610.
21. Hasler G., Drevets W.C., Manji H.K., Charney D.S. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004, 29:1765-1781.
22. Heuser I., Deuschle M., Luppa P., Schweiger U., Standhardt H., Weber B. Increased diurnal plasma concentrations of dehydroepiandrosterone in depressed patients. J. Clin. Endocrinol. Metab. 1998, 83:3130-3133.
23. Hsiao C.C. Difference in pre- and post-treatment plasma DHEA levels were significantly and positively correlated with difference in pre- and post-treatment Hamilton depression scores following successful therapy for major depression. Psychoneuroendocrinology 2006, 31:839-846.
24. Hsiao F.H., Jow G.M., Lai Y.M., Chen Y.T., Wang K.C., Ng S.M., Ho R.T., Chan C.L., Yang T.T. The long-term effects of psychotherapy added to pharmacotherapy on morning to evening diurnal cortisol patterns in outpatients with major depression. Psychother. Psychosom. 2011, 80:166-172.
25. Juster R.P., McEwen B.S., Lupien S.J. Allostatic load biomarkers of chronic stress and impact on health and cognition. Neurosci. Biobehav. Rev. 2010, 35:2-16.
26. Key T., Appleby P., Barnes I., Reeves G., Endogenous H., Breast Cancer Collaborative Group Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl. Cancer Inst. 2002, 94:606-616.
27. Kurita H., Maeshima H., Kida S., Matsuzaka H., Shimano T., Nakano Y., Baba H., Suzuki T., Arai H. Serum dehydroepiandrosterone (DHEA) and DHEA-sulfate (S) levels in medicated patients with major depressive disorder compared with controls. J. Affect. Disord. 2013, 146:205-212.
28. Lamers F., Vogelzangs N., Merikangas K.R., de Jonge P., Beekman A.T., Penninx B.W. Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol. Psychiatry 2013, 18:692-699.
29. Lennartsson A.K., Theorell T., Kushnir M.M., Bergquist J., Jonsdottir I.H. Perceived stress at work is associated with attenuated DHEA-S response during acute psychosocial stress. Psychoneuroendocrinology 2013, 38:1650-1657.
30. Lok A., Mocking R.J., Ruhé H.G., Visser I., Koeter M.W., Assies J., Bockting C.L., Olff M., Schene A.H. Longitudinal hypothalamic-pituitary-adrenal axis trait and state effects in recurrent depression. Psychoneuroendocrinology 2012, 37:892-902.
31. Maninger N., Wolkowitz O.M., Reus V.I., Epel E.S., Mellon S.H. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Front. Neuroendocrinol. 2009, 30:65-91.
32. Markopoulou K., Papadopoulos A., Juruena M.F., Poon L., Pariante C.M., Cleare A.J. The ratio of cortisol/DHEA in treatment resistant depression. Psychoneuroendocrinology 2009, 34:19-26.
33. McEwen B.S. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol. Rev. 2007, 87:873-904.
34. Michael A., Jenaway A., Paykel E.S., Herbert J. Altered salivary dehydroepiandrosterone levels in major depression in adults. Biol. Psychiatry 2000, 48:989-995.
35. Morita T., Senzaki K., Ishihara R., Umeda K., Iwata N., Nagai T., Hida H., Nabeshima T., Yukawa K., Ozaki N., Noda Y. Plasma dehydroepiandrosterone sulfate levels in patients with major depressive disorder correlate with remission during treatment with antidepressants. Hum. Psychopharmacol. 2014, 29:280-286.
36. Mouthaan J., Sijbrandij M., Luitse J.S., Goslings J.C., Gersons B.P., Olff M. The role of acute cortisol and DHEAS in predicting acute and chronic PTSD symptoms. Psychoneuroendocrinology 2014, 45:179-186.
37. Olff M., de Vries G.J., Guzelcan Y., Assies J., Gersons B.P. Changes in cortisol and DHEA plasma levels after psychotherapy for PTSD. Psychoneuroendocrinology 2007, 32:619-626.
38. Pariante C.M. The role of multi-drug resistance p-glycoprotein in glucocorticoid function: studies in animals and relevance in humans. Eur. J. Pharmacol. 2008, 583:263-271.
39. Pariante C.M., Thomas S.A., Lovestone S., Makoff A., Kerwin R.W. Do antidepressants regulate how cortisol affects the brain?. Psychoneuroendocrinology 2004, 29:423-447.
40. Paslakis G., Luppa P., Gilles M., Kopf D., Hamann-Weber B., Lederbogen F., Deuschle M. Venlafaxine and mirtazapine treatment lowers serum concentrations of dehydroepiandrosterone-sulfate in depressed patients remitting during the course of treatment. J. Psychiatr. Res. 2010, 44:556-560.
41. Peixoto C., Devicari Cheda J.N., Nardi A.E., Veras A.B., Cardoso A. The effects of dehydroepiandrosterone (DHEA) in the treatment of depression and depressive symptoms in other psychiatric and medical illnesses: a systematic review. Curr. Drug Targets 2014, 15:901-914.
42. Ritsner M., Gibel A., Maayan R., Ratner Y., Ram E., Modai I., Weizman A. State and trait related predictors of serum cortisol to DHEA(S) molar ratios and hormone concentrations in schizophrenia patients. Eur. Neuropsychopharmacol. 2007, 17:257-264.
43. Ruhé H.G., Khoenkhoen S.J., Ottenhof K.W., Koeter M.W., Mocking R.J., Schene A.H. Longitudinal effects of the SSRI paroxetine on salivary cortisol in major depressive disorder. Psychoneuroendocrinology 2015, 52:261-271.
44. Sakr H.F., Khalil K.I., Hussein A.M., Zaki M.S., Eid R.A., Alkhateeb M. Effect of dehydroepiandrosterone (DHEA) on memory and brain derived neurotrophic factor (BDNF) in a rat model of vascular dementia. J. Physiol. Pharmacol. 2014, 65:41-53.
45. Schule C., Baghai T.C., Eser D., Schwarz M., Bondy B., Rupprecht R. Effects of mirtazapine on dehydroepiandrosterone-sulfate and cortisol plasma concentrations in depressed patients. J. Psychiatr. Res. 2009, 43:538-545.
46. Sripada R.K., Marx C.E., King A.P., Rajaram N., Garfinkel S.N., Abelson J.L., Liberzon I. DHEA enhances emotion regulation neurocircuits and modulates memory for emotional stimuli. Neuropsychopharmacology 2013, 38:1798-1807.
47. Stetler C., Miller G.E. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom. Med. 2011, 73:114-126.
48. Stewart P.M. Aging and fountain-of-youth hormones. N. Engl. J. Med. 2006, 355:1724-1726.
49. Vreeburg S.A., Kruijtzer B.P., van Pelt J., van Dyck R., DeRijk R.H., Hoogendijk W.J., Smit J.H., Zitman F.G., Penninx B.W. Associations between sociodemographic, sampling and health factors and various salivary cortisol indicators in a large sample without psychopathology. Psychoneuroendocrinology 2009, 34:1109-1120.
50. Whetzel C.A., Klein L.C. A Functional Assessment of Salivary Dehydroepiandrosterone Sulfate (DHEA-S) in Response to Acute Stress 2008, 1. Pennsylvania State University, University Park, PA, (electronic document (227p.)).
51. Whetzel C.A., Klein L.C. Measuring DHEA-S in saliva: time of day differences and positive correlations between two different types of collection methods. BMC Res. Notes 2010, 3:204.
52. Young A.H., Gallagher P., Porter R.J. Elevation of the cortisol-dehydroepiandrosterone ratio in drug-free depressed patients. Am. J. Psychiatry 2002, 159:1237-1239.
53. Zelcer N., Reid G., Wielinga P., Kuil A., van der Heijden I., Schuetz J.D., Borst P. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem. J. 2003, 371:361-367.